* Selvom farmakokinetikken for ciprofloxacin er uændret hos voksne patienter med cystisk fibrose, skal den lavere kropsvægt hos disse patienter tages i betragtning, når dosis bestemmes.
* Although the pharmacokinetics of ciprofloxacin remains unchanged in adult patients with cystic fibrosis, the low bodyweight of these patients should be taken into consideration when determining dosage.